Future large-scale, multi-institutional studies are warranted to validate RUNX2 as a prognostic marker, clarify the modulatory role of WWOX, and explore whether targeting this pathway can improve clinical outcomes in patients with Ewing sarcoma. This evidence concerns the gene RUNX2 and Ewing sarcoma.